EN FR Search form Search Main menu ABOUT US RESPONSIBILITY SOLUTIONS EXPERTISE EDUCATION INVESTORS NEWSROOM CAREERS CONTACT US You are here HomeNewsroomAbout bioMérieux NEWSROOM PRESS RELEASES bioMérieux CORPORATE CALENDAR MEDIA CENTER Corporate brochure Annual Report Press Contacts ABOUT BIOMÉRIEUX About bioMérieux PRESS RELEASE October 21, 2021 Baxter and bioMérieux announce CE mark for NEPHROCLEAR™ CCL14 te... October 21, 2021 bioMérieux – Third-Quarter 2021 Business Review September 13, 2021 A survey in 5 European countries about sepsis demonstrates the lack... September 01, 2021 bioMérieux – First-Half 2021 Results Annual Report Clinical Solutions To discover all of our products for Clinical applications, please visit bioMérieux Diagnostics website. Industry Solutions To discover all of our products for industrial microbiological control, please visit our bioMérieux Industry website. Pioneering Diagnostics A world leader in the field of in vitro diagnostics for over 55 years, bioMérieux is present in 44 countries and serves more than 160 countries with the support of a large network of distributors. In 2020, revenues reached €3.1 billion, with over 90% of international sales (outside of France). bioMérieux provides diagnostic solutions (systems, reagents, software, services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMérieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0013280286). PIONEERING DIAGNOSTICS bioMérieux Worldwide > Our Specific Websites > Our communities > LEGAL NOTICE PRIVACY COOKIE POLICY CONTACT Copyright 2021 bioMérieux SA biomerieux.com